drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
An autologous, gene-modified CD19/CD20 dual-targeting CAR T-cell therapy given as a single IV infusion after conditioning; the CAR redirects T cells to CD19 and CD20 on malignant B cells to trigger cytotoxic killing and induce B-cell aplasia.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous gene-modified T cells engineered to express a dual-specific chimeric antigen receptor that binds CD19 and CD20 on B cells; antigen engagement activates T-cell signaling, proliferation, cytokine release, and perforin/granzyme-mediated cytotoxic killing of malignant B cells, leading to B-cell aplasia.
drug_name
LYL314
nct_id_drug_ref
NCT05826535